Don’t miss – Page 187 – Endpoints News

SIGN UP

In the midst of a deal spree, Bayer turns to veteran J&J dealmaker Marianne De Backer to bring home the technology

4 years ago

Ardelyx's lead drug tenapanor scores in second hyperphosphatemia study, shares leap

4 years ago

Vertex gambles $950M on biotech buyout, hunting a cure for diabetes

4 years ago

RA Capital-backed cell therapy player in the neoantigen game grabs a $121M megaround to fund first human studies

4 years ago

A new PCSK9 player draws rave reviews for inclisiran. Can a marketing war with Amgen be far behind?

4 years ago

Alexion hit by surprise inter partes review as Amgen challenges Soliris patents

4 years ago

Remember that post-marketing trial? New study confirms many drugmakers don’t do them — half drag their feet

4 years ago

Novartis preps a 2020 launch in multiple sclerosis as 2 successful pivotal trials set stage for an assault on Roche’s new star franchise

4 years ago

AbbVie’s $10B Rova-T play ends in one last failure — R&D team shuts it all down

4 years ago

Amgen’s legendary lawyer corps loses a major court fight attempting to quash PCSK9 rival from Sanofi, Regeneron

4 years ago

Tears for FAERS: Another FAERS disaster rumor slams Vertex shares in a Wall Street melee — but this time the tempest passed quickly

4 years ago

The Woodford effect: Teetering on the edge, his co-investors are feeling the pain — and they want it to stop

4 years ago

AstraZeneca wins a round in their PhIII COPD bout with GSK — but can they catch up?

4 years ago

Immatics scores $75M upfront in TCR deal with Celgene as interest in tech burgeons

4 years ago

Top FDA exec Edward Cox jumps ship and joins Regeneron as new regulatory VP

4 years ago

Franchise killer: Are Regeneron and Sanofi about to get handed their walking papers on PCSK9?

4 years ago

After inking a string of pipeline deals, Boehringer Ingelheim is doing a makeover of the top executive team

4 years ago

FibroGen founder and CEO Thomas Neff dies unexpectedly as lead drug nears commercial threshold

4 years ago

Top 20 by revenue: New analysis highlights huge impact of tax reform on many — but not all — of the top pharma giants

4 years ago

Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene

4 years ago

‘Absolute standout’ biopharma analyst Mark Schoenebaum has died

4 years ago

FDA asks why Novartis took two months to launch formal internal probe, after AveXis flagged data manipulation

4 years ago

GSK's Hal Barron heralds their second positive pivotal for crucial anti-BCMA therapy, pointing to a push for quick OKs in a crowded field

4 years ago

An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle up?

4 years ago

First page Previous page 184 185 186187188 189 190 Next page Last page